Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • Metabolism Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Michael B. Kastan Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • Metabolism Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Michael B. Kastan Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Genomics

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer

Simon Garinet, Géraldine Pignot, Sophie Vacher, Constance Le Goux, Anne Schnitzler, Walid Chemlali, Nanor Sirab, Nicolas Barry Delongchamps, Marc Zerbib, Mathilde Sibony, Yves Allory, Diane Damotte and Ivan Bieche
Simon Garinet
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Simon.garinet@aphp.fr
Géraldine Pignot
Unité de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Vacher
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie Vacher
Constance Le Goux
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Schnitzler
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walid Chemlali
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanor Sirab
INSERM U955, Equipe 7, Université Paris-Est, Créteil, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Barry Delongchamps
Hôpital Cochin, Service d'Urologie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Zerbib
Hôpital Cochin, Service d'Urologie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathilde Sibony
Service d'Anatomopathologie, Hôpital Cochin, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Allory
Service d'Anatomopathologie, Institut Curie, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Damotte
Service d'Anatomopathologie, Hôpital Cochin, Paris, France.INSERM U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France.Université Paris Descartes, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Bieche
Unité de Pharmacogénomique, Service de génétique, Institut Curie, Paris, France.Université Paris Descartes, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-18-0363 Published February 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Numerous pangenomic studies identified protein-coding genes and signaling pathways involved in bladder carcinogenesis. However, noncoding somatic alterations remain unexplored. A recent study revealed a mutational hotspot in intron 6 of GPR126 gene in 2.7% of a large breast cancer series. As GPR126 is highly expressed in bladder tissues, we investigated here the prevalence and the prognostic significance of these mutations in bladder cancer. We analyzed a cohort of 103 bladder cancers including 44 nonmuscle-invasive bladder cancers (NMIBC) and 59 muscle-invasive bladder cancers (MIBC). GPR126 mutations were analyzed by high-resolution melting and Sanger sequencing, and GPR126 expression levels were assessed using real-time quantitative RT-PCR. In NMIBC, somatic GPR126 noncoding mutations occurred in 47.7% of samples and were negatively associated with GPR126 mRNA levels. GPR126 mutations had higher frequencies in nonsmoker patients and were associated with a prior history of NMIBC. GPR126 overexpression was detected in 70.5% of samples. GPR126 mutation and overexpression status were not associated with outcome. In MIBC, somatic GPR126 mutations occurred in 44.1% of samples. Mutations were more frequent in females. GPR126 overexpression was detected in 27.1% of the sample. A trend toward significance was observed between GPR126 overexpression and better outcome. We identified the second most frequent mutational hotspot after TERT promoter (∼70%) in bladder cancer, with a mutation rate of approximately 50%.

Implications: The GPR126 intronic mutational hotspot could be a promising clinical biomarker candidate to monitor tumor burden using circulating tumor DNA in bladder cancer.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

  • Received April 11, 2018.
  • Revision received August 1, 2018.
  • Accepted October 18, 2018.
  • Published first November 6, 2018.
  • ©2018 American Association for Cancer Research.
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase Short Term Access

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top
Molecular Cancer Research: 17 (2)
February 2019
Volume 17, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
Citation Tools
High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer
Simon Garinet, Géraldine Pignot, Sophie Vacher, Constance Le Goux, Anne Schnitzler, Walid Chemlali, Nanor Sirab, Nicolas Barry Delongchamps, Marc Zerbib, Mathilde Sibony, Yves Allory, Diane Damotte and Ivan Bieche
Mol Cancer Res February 1 2019 (17) (2) 469-475; DOI: 10.1158/1541-7786.MCR-18-0363

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer
Simon Garinet, Géraldine Pignot, Sophie Vacher, Constance Le Goux, Anne Schnitzler, Walid Chemlali, Nanor Sirab, Nicolas Barry Delongchamps, Marc Zerbib, Mathilde Sibony, Yves Allory, Diane Damotte and Ivan Bieche
Mol Cancer Res February 1 2019 (17) (2) 469-475; DOI: 10.1158/1541-7786.MCR-18-0363
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Germline Variants Are Predictive of Survival in LGG Patients
  • Cisplatin Shapes Osteosarcoma Clonal Evolution
  • Multiclonality and Branched Evolution of Endometrial Cancer
Show more Genomics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement